ECSP10010153A - Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos - Google Patents

Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos

Info

Publication number
ECSP10010153A
ECSP10010153A EC2010010153A ECSP10010153A ECSP10010153A EC SP10010153 A ECSP10010153 A EC SP10010153A EC 2010010153 A EC2010010153 A EC 2010010153A EC SP10010153 A ECSP10010153 A EC SP10010153A EC SP10010153 A ECSP10010153 A EC SP10010153A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical compositions
compositions containing
bradiquinine
antagonists
hialuronic acid
Prior art date
Application number
EC2010010153A
Other languages
English (en)
Inventor
Sandro Giuliani
Carlo Alberto Maggi
Laura Quartara
Original Assignee
Luso Farmaco Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luso Farmaco Inst filed Critical Luso Farmaco Inst
Publication of ECSP10010153A publication Critical patent/ECSP10010153A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Se describen las composiciones farmacéuticas que contienen, como ingredientes activos, una mezcla de un polímero de ácido hialurónico con un antagonista del receptor de bradiquinina B2. Se ha comprobado que dichas composiciones son especialmente efectivas en el tratamiento de enfermedades articulares degenerativas tales como osteoartritis usando inyecciones intraarticulares.
EC2010010153A 2007-11-23 2010-05-05 Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos ECSP10010153A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002225A ITMI20072225A1 (it) 2007-11-23 2007-11-23 "composizioni farmaceutiche a base di antagonisti della bradichinina ed acido ialuronico e loro uso"
PCT/EP2008/009451 WO2009065507A2 (en) 2007-11-23 2008-11-10 Pharmaceutical compositions containing bradykinin antagonists and hyaluronic acid, and uses thereof

Publications (1)

Publication Number Publication Date
ECSP10010153A true ECSP10010153A (es) 2010-06-29

Family

ID=40314753

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010153A ECSP10010153A (es) 2007-11-23 2010-05-05 Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos

Country Status (40)

Country Link
US (1) US9101627B2 (es)
EP (1) EP2222275B1 (es)
JP (1) JP5383695B2 (es)
KR (1) KR101585868B1 (es)
CN (1) CN101868225B (es)
AP (1) AP2628A (es)
AR (1) AR069407A1 (es)
AT (1) ATE529096T1 (es)
AU (1) AU2008328311B2 (es)
BR (1) BRPI0820402A2 (es)
CA (1) CA2706398C (es)
CL (1) CL2008003475A1 (es)
CO (1) CO6270301A2 (es)
CR (1) CR11457A (es)
CY (1) CY1112134T1 (es)
DK (1) DK2222275T3 (es)
EA (1) EA017626B1 (es)
EC (1) ECSP10010153A (es)
ES (1) ES2374861T3 (es)
GE (1) GEP20125602B (es)
HN (1) HN2010001037A (es)
HR (1) HRP20110904T1 (es)
IL (1) IL205860A (es)
IT (1) ITMI20072225A1 (es)
MA (1) MA31913B1 (es)
MX (1) MX2010005484A (es)
MY (1) MY148685A (es)
NI (1) NI201000087A (es)
NZ (1) NZ585514A (es)
PA (1) PA8804801A1 (es)
PE (1) PE20091422A1 (es)
PL (1) PL2222275T3 (es)
PT (1) PT2222275E (es)
RS (1) RS52045B (es)
SI (1) SI2222275T1 (es)
TN (1) TN2010000215A1 (es)
TW (1) TWI448292B (es)
UA (1) UA97867C2 (es)
WO (1) WO2009065507A2 (es)
ZA (1) ZA201003586B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016028176A2 (pt) * 2014-05-30 2017-08-22 Mykolaivna Derkach Nataliia solução estabilizada com base em duas substâncias ativas, método para preparar a solução estabilizada e composições farmacêuticas com base na solução estabilizada de substâncias ativas
CN107106594A (zh) * 2014-12-26 2017-08-29 生化学工业株式会社 改善眼的自觉症状的制剂和方法
US12371683B2 (en) 2018-07-25 2025-07-29 Alteogen Inc. Hyaluronidase variants and pharmaceutical composition comprising the same
CN120053667A (zh) 2019-03-25 2025-05-30 阿特根公司 用于皮下注射的包含人透明质酸酶ph20变体和药物的药物组合物
US11401303B2 (en) * 2020-06-15 2022-08-02 Taian City Qihang Biotechnology Co. Synthetic peptide BRAP and application in preparation of anti-inflammatory drug for COVID-19 thereof
EP4194551A4 (en) 2020-08-07 2024-08-28 Alteogen, Inc. PROCESS FOR PRODUCING RECOMBINANT HYALURONIDASE

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635489B2 (en) * 2001-05-18 2009-12-22 Leneau Holdings, Llc Ingestion of hyaluronic acid for improved joint health
ITMI20021247A1 (it) * 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) * 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"

Also Published As

Publication number Publication date
NZ585514A (en) 2012-01-12
ITMI20072225A1 (it) 2009-05-24
EA201000678A1 (ru) 2010-12-30
CR11457A (es) 2010-11-05
US20100292156A1 (en) 2010-11-18
EA017626B1 (ru) 2013-01-30
JP2011504473A (ja) 2011-02-10
BRPI0820402A2 (pt) 2015-05-19
TWI448292B (zh) 2014-08-11
SI2222275T1 (sl) 2012-01-31
CN101868225B (zh) 2013-06-12
DK2222275T3 (da) 2012-01-02
AP2628A (en) 2013-03-26
KR20100096106A (ko) 2010-09-01
HK1149714A1 (en) 2011-10-14
HRP20110904T1 (hr) 2011-12-31
CL2008003475A1 (es) 2009-03-27
PA8804801A1 (es) 2009-06-23
HN2010001037A (es) 2012-12-10
CA2706398A1 (en) 2009-05-28
CY1112134T1 (el) 2015-11-04
WO2009065507A3 (en) 2009-09-03
CN101868225A (zh) 2010-10-20
CA2706398C (en) 2016-07-05
PT2222275E (pt) 2012-01-16
US9101627B2 (en) 2015-08-11
MY148685A (en) 2013-05-31
GEP20125602B (en) 2012-08-10
ATE529096T1 (de) 2011-11-15
PE20091422A1 (es) 2009-10-17
JP5383695B2 (ja) 2014-01-08
ES2374861T3 (es) 2012-02-22
RS52045B (sr) 2012-04-30
IL205860A0 (en) 2010-11-30
WO2009065507A2 (en) 2009-05-28
EP2222275B1 (en) 2011-10-19
EP2222275A2 (en) 2010-09-01
AR069407A1 (es) 2010-01-20
NI201000087A (es) 2011-07-18
AU2008328311B2 (en) 2013-02-28
IL205860A (en) 2013-01-31
ZA201003586B (en) 2011-08-31
PL2222275T3 (pl) 2012-03-30
MA31913B1 (fr) 2010-12-01
TW200927151A (en) 2009-07-01
AU2008328311A1 (en) 2009-05-28
MX2010005484A (es) 2010-06-07
KR101585868B1 (ko) 2016-01-22
UA97867C2 (ru) 2012-03-26
CO6270301A2 (es) 2011-04-20
AP2010005265A0 (en) 2010-06-30
TN2010000215A1 (en) 2011-11-11

Similar Documents

Publication Publication Date Title
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
BR112018004536A2 (pt) peptídeos de endereçamento à cartilagem
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
EA201270467A1 (ru) Полициклические соединения в качестве антагонистов рецепторов лизофосфатидной кислоты
EA201101709A1 (ru) Полициклические антагонисты рецепторов лизофосфатидной кислоты
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
PH12015501737B1 (en) Androgen receptor modulators and uses thereof
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
BR112014012789A2 (pt) agentes terapêuticos compreendendo sequências de aminoácidos de insulina
ECSP10010153A (es) Composiciones farmacéuticas que contienen antagonistas de bradiquinina y ácido hialurónico y sus usos
BR112014027981A2 (pt) compostos do tipo fumagilol e métodos de produção e utilização dos mesmos
CL2009001006A1 (es) Compuestos derivados del acido 4-dimetil-aminobutirico; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento o profilaxis de enfermedades tales como hiperglucemia, diabetes e hipertension entre otras.
CL2015000053A1 (es) Composicion líquida oral pediátrica que comprende nepadutant y tpgs; proceso para prepararla; util en el tratamiento de enfermedades intestinales.
ECSP11010752A (es) Composiciones farmacéuticas basadas en antagonistas del receptor de quinina b2 y corticosteroides
UY32679A (es) Antagonistas policíclicos de receptores de ácido lisofosfatidico
MX380487B (es) Fructanos de agave como excipiente farmacéutico funcional en una forma de dosificación de liberación inmediata.
EA200900172A1 (ru) Фармацевтическая композиция для контрацепции
UY36556A (es) Nuevas composiciones farmacéuticas para el tratamiento de la hipertensión